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B
uruli ulcer is a disease of skin and soft tissue with the 
potential to leave sufferers scarred and disabled. It is 
caused by an environmental pathogen, Mycobacterium 
ulcerans, that produces a destructive toxin. The exact mode of 
transmission is unclear. The main burden of disease falls on 
children living in sub-Saharan Africa, but healthy people of 
all ages, races, and socioeconomic classes are susceptible.   
History and Epidemiology
M. ulcerans is the third most common mycobacterial pathogen 
of humans, after M. tuberculosis and M. leprae (which cause 
tuberculosis and leprosy, respectively). The deﬁ  nitive 
description of M. ulcerans was published in 1948, when 
MacCallum and others in Australia reported six cases of 
an unusual skin infection caused by a mycobacterium that 
could only be cultured when the incubation temperature was 
set lower than for M. tuberculosis [1]. In Africa, large ulcers 
almost certainly caused by M. ulcerans had been described 
by Sir Albert Cook in 1897 and by Kleinschmidt in northeast 
Congo during the 1920s [2]. 
Prior to the 1980s, foci of M. ulcerans infection were 
reported in several countries in sub-Saharan Africa including 
Congo [3], Uganda [4], Gabon, Nigeria [5], Cameroon, 
and Ghana [6]. The Uganda Buruli Group coined the name 
“Buruli ulcer” because the cases they described were ﬁ  rst 
detected in Buruli county, near lake Kyoga [7].
Since 1980, dramatic increases in the incidence of Buruli 
ulcer have been reported from the West African countries 
of Benin [8], Côte d’Ivoire [9], and Ghana [10]. New foci 
were also discovered recently in Togo [11] and Angola [12]. 
A characteristic of Buruli ulcer is its focal distribution even 
within endemic regions, and obtaining accurate disease 
burden estimates is difﬁ  cult. However, in some highly 
endemic districts in Ghana, point prevalence has been 
estimated to be as high as 150.8/100,000 individuals [10], and 
in southern Benin, a recent study has reported detection rates 
of 21.5/100,000 per year, higher than for either tuberculosis 
or leprosy [8]. In West Africa, about 25% of people affected 
by the disease, mostly children, are left with permanent 
disabilities. The disease is also endemic in several other 
countries outside Africa, including rural areas of Papua New 
Guinea, Malaysia, French Guiana, and Mexico (Figure 1). 
In Australia, the disease remains uncommon, but there have 
been increases in both incidence and the number of endemic 
areas in the last 15 years [13,14].
Causative Organism and Pathology
Mycobacterium ulcerans is a slow-growing environmental 
mycobacterium that can be cultured from human lesions 
on mycobacterial medium at 30–32 °C [15]. Histological 
specimens typically show large clumps of extracellular acid-
fast organisms surrounded by areas of necrosis and a poor or 
absent inﬂ  ammatory response [16]. 
Subcutaneous fat is particularly affected, but underlying 
bone may also become involved in advanced cases [15]. 
The pathogenesis and histological appearance is explained 
by a recently identiﬁ  ed diffusible lipid toxin, mycolactone 
[17]. Later in the natural history of the disease, the 
immunosuppressive effect of the toxin is somehow overcome 
by the host, immunity develops, and healing commences.
Clinical Features
The classic lesion is a necrotic skin ulcer with deeply 
undermined edges (Figure 2). Any part of the body can be 
Neglected Diseases
Open access, freely available online
The Neglected Diseases section focuses attention either on a speciﬁ  c disease or 
describes a novel strategy for approaching neglected health issues in general.
April 2005  |  Volume 2  |  Issue 4  |  e108
Buruli Ulcer (M. ulcerans Infection): 
New Insights, New Hope for Disease Control
Paul D. R. Johnson*, Timothy Stinear, Pamela L. C. Small, Gerd Plushke, Richard W. Merritt, Francoise Portaels, Kris Huygen, John 
A. Hayman, Kingsley Asiedu
Citation: Johnson PDR, Stinear T, Small PLC, Plushke G, Merritt RW, et al. (2005) Buruli 
ulcer (M. ulcerans infection): New insights, new hope for disease control. PLoS Med 
2(4): e108.
Copyright: © 2005 Johnson et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original work is 
properly cited. 
Abbreviations: PCR, polymerase chain reaction; Th, T helper; WHO, World Health 
Organization
Paul D. R. Johnson is at the Department of Infectious Diseases, Austin Health, 
Heidelberg, Australia, at the University of Melbourne, Australia, and at the 
Department of Microbiology, Monash University, Melbourne, Australia. Timothy 
Stinear is at the Department of Microbiology, Monash University, Melbourne, 
Australia. Pamela L. C. Small is at the Department of Microbiology, University of 
Tennessee, Knoxville, Tennessee, United States of America. Gerd Pluschke is at the 
Department of Molecular Immunology, Swiss Tropical Institute, Basel, Switzerland. 
Richard W. Merritt is at the Department of Entomology, Michigan State University, 
East Lansing, Michigan, United States of America. Francoise Portaels is at the 
Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium. 
Kris Huygen is at the Department of Mycobacterial Immunology, WIV-Pasteur 
Institute Brussels, Belgium. John A. Hayman is at the Department of Anatomy 
and Cell Biology, Monash University, Melbourne, Australia. Kingsley Asiedu is at 
the Department of Communicable Diseases, World Health Organization, Geneva, 
Switzerland.
Competing Interests: PLCS is listed as an inventor on a patent for mycolactone; 
PDRJ, TS, and PLCS are listed as inventors on a provisional patent for the PKS locus 
that makes mycolactone. However, any ﬁ  nancial beneﬁ  t that may arise from these 
patents would be in the ﬁ  eld of either cancer medicine (mycolactone may inhibit 
some cell functions) or combinatorial chemistry, rather than Buruli ulcer. 
*To whom correspondence should be addressed. E-mail: Paul.Johnson@austin.org.
au
DOI: 10.1371/journal.pmed.0020108
The main burden of disease falls on 
children living in sub-Saharan Africa.PLoS Medicine  |  www.plosmedicine.org 0283
affected, but most lesions occur on limbs. The ulcers are 
slowly progressive and usually painless, and the patient is 
usually systemically well, which may explain why sufferers 
often delay seeking medical assistance. Early Buruli lesions 
may initially appear as a mobile subcutaneous nodule, a 
papule, or a raised plaque. 
A subgroup of patients present with rapidly progressive 
oedema of a whole limb, abdominal wall, or side of the face 
without an obvious focal lesion. Part or all of the affected area 
will subsequently ulcerate, although anecdotal reports suggest 
that timely antibiotic therapy may greatly reduce the resulting 
necrosis [18]. 
Treatment 
The aim of treatment is to halt the infection and repair 
existing damage. Large ulcers are usually treated surgically 
to remove necrotic tissue and to graft the resulting defect. 
Relapse after surgery may occur in 18%–47% of cases [19], 
so surgeons commonly ensure wide excision margins in the 
hope of curing the infection. 
Traditionally, drug therapy has been considered 
ineffective, but recent data suggest that combinations of 
anti-mycobacterial antibiotics that include rifampicin and 
either streptomycin or amikacin are able to kill M. ulcerans 
in human lesions [14,20]. Provisional guidelines now 
recommend the use of selected anti-mycobacterial drugs, 
usually combined with surgery, for the treatment of Buruli 
ulcer [21]. 
Prevention of Disabilities 
Untreated Buruli ulcer will eventually subside with the 
gradual development of host immunity in most cases. 
However, by this time, tissue damage may be very extensive 
and healing by scar can lead to permanent functional and 
cosmetic deformity (Figure 3). Successful treatment will 
shorten the course of the disease and minimise deformity. 
Skilled surgery, expert post-operative nursing care, and 
restorative physiotherapy are often required to achieve good 
outcomes. The cost of this may be beyond the means of 
local rural health services. Even in Australia, where there is 
universal access to health care, the cost and complexity of 
treating M. ulcerans infections can be considerable [22].
Public Health Efforts
Case control studies have suggested that farming activities 
close to rivers in endemic areas are a risk factor for Buruli 
ulcer [9], but for farmers involved in subsistence agriculture, 
avoidance of riverine areas is difﬁ  cult. A recent study from 
Ghana has suggested that swimming in rivers may also be 
an independent risk factor [23]. To date, the main focus 
of public health efforts has been on early detection and 
treatment, which greatly reduce morbidity and cost [8,24].
Why Has Buruli Ulcer Been Neglected until Now?
Despite its long history, Buruli ulcer has gone largely 
unnoticed until recently. Buruli ulcer typically occurs in poor 
rural communities with little economic or political inﬂ  uence. 
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Figure 1. Countries Reporting Buruli Ulcer
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Rural isolation may mean that national surveillance systems 
do not immediately detect the appearance of new outbreaks. 
Affected populations may believe that there is no effective 
medical treatment for the disease, which discourages them 
from seeking assistance [25,26]. 
In the developed world, Buruli ulcer is frequently omitted 
from standard medical texts and undergraduate medical 
courses. The absence of a potentially proﬁ  table market has 
meant that there has been little private investment to date 
in drug and vaccine development or in research to improve 
prospects for better control.
Future Directions and the End of Obscurity
Global Buruli Ulcer Initiative. In December 1997, Hiroshi 
Nakajima, then Director-General of the World Health 
Organization (WHO), announced that WHO would take 
the lead to mobilise the world’s expertise and resources 
to ﬁ  ght the emergence of Buruli ulcer as a serious public 
health problem. In 1998, WHO launched the Global Buruli 
Ulcer Initiative to coordinate control and research efforts, 
and organised the ﬁ  rst International Conference on Buruli 
ulcer control and research in Yamoussoukro, Côte d’Ivoire. 
The resulting “Yamoussoukro Declaration on Buruli Ulcer” 
drew attention to the severity of the disease as an emerging 
public health problem and expressed concern about its many 
poorly understood features. In May 2004, the World Health 
Assembly adopted a resolution on Buruli ulcer that called 
for increasing surveillance and control, and for intensiﬁ  ed 
research to develop tools to diagnose, treat, and prevent the 
disease [27]. The attention of the affected countries, donor 
agencies, nongovernmental organisations, and the research 
community has been captured by these and other initiatives, 
and we are now entering an exciting period of rapidly 
expanding knowledge and interest in the disease. These 
developments will ensure that Buruli ulcer is not neglected 
again.
Recent research on transmission. For over 50 years 
we have known that proximity to marshes and wetlands, 
often created as a result of some human environmental 
disturbance, is a risk factor for infection [28], but the exact 
mode of transmission remains an enigma. M. ulcerans was 
ﬁ  rst detected in the environment in the 1990s by Australian 
researchers using polymerase chain reaction (PCR) [29,30]. 
Subsequently, PCR was used by others to identify M. ulcerans 
in aquatic insects obtained from endemic areas in Africa [31], 
leading to the hypothesis that M. ulcerans may be transmitted 
by biting water bugs of the insect order Hemiptera 
(Naucoridae and Belostomatidae; Figure 4). 
In support of this hypothesis, M. ulcerans has been 
detected in the salivary glands of Naucoris sp., and has been 
transmitted to laboratory mice via this aquatic insect [32,33]. 
There is additional evidence that M. ulcerans DNA can be 
detected by PCR in other aquatic insect predators (e.g., 
Odonata and Coleoptera), as well as in aquatic snails, small 
ﬁ  sh, and the bioﬁ  lm of aquatic plants [34]. Despite this, 
only two pure cultures of M. ulcerans have been obtained 
from environmental sources. In Australia, it has been 
postulated that aerosols arising from contaminated water may 
disseminate M. ulcerans and infect humans via the respiratory 
tract, or through contamination of skin lesions and minor 
abrasions [35,36], but this has yet to be proven. Recent 
progress has been rapid, but the exact mode of transmission, 
the key important reservoir species, and transmission of 
M. ulcerans through the aquatic food chain remain to be 
elucidated. 
Immune response. The immune mechanisms involved in 
protection against Buruli ulcer are also largely unknown at 
present. Interestingly, peripheral blood mononuclear cells 
obtained from people with a past or current M. ulcerans 
infection typically show a strong T helper (Th)–2 cytokine 
response when exposed in vitro to M. ulcerans. In contrast, 
samples obtained from their household contacts (exposed 
healthy controls) exhibit a Th-1 immune response, suggesting 
that natural resistance may be determined by cell-mediated 
immune mechanisms directed against intracellular organisms 
[37]. In one fascinating case study, it has been shown that the 
development of ulcerative M. ulcerans disease is associated 
with a shift from the Th-1 to the Th-2 phenotype [38]. 
Interleukin-10 may be a key cytokine that mediates local Th 
phenotype switching within nodules and ulcers [39].
Antibodies may also have a protective role against M. 
ulcerans, as the pathogen is extracellular during active disease. 
Experimental infection of mice genetically inactivated 
in various compartments of the immune response (B 
lymphocytes, Th cells, and cytolytic T lymphocytes, cytokines, 
and monokines) will help us to understand how host 
immunity is acquired. 
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Figure 2. M. ulcerans Infection of the Shin of an 11-Year-Old Boy, Coastal 
Victoria, Australia
A closer view, revealing deep undermining, is shown in the 
second panel.
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Developing new drugs. M. ulcerans is susceptible to several 
anti-mycobacterial drugs in vitro, but the most promising 
results in the mouse footpad model were obtained with a 
combination of rifampicin and amikacin [40]. A human 
trial has recently shown that early nodular lesions may be 
rendered culture-negative after a minimum of four weeks 
therapy with rifampicin plus streptomycin [14,20]. 
Further research to identify cheap, safe, and effective oral 
combinations that can be used as an adjuvant to surgery or 
that could even replace surgery for early lesions is urgently 
required. At least one new compound, which appears safe for 
humans in early phase I trials, has remarkable activity in vitro 
against many mycobacterial species including M. tuberculosis 
and M. ulcerans [41]. 
M. ulcerans toxin. M. ulcerans makes a family of toxic 
macrolides, the mycolactones, that are required for virulence 
[17]. Mycolactone causes cells in cell culture assays to 
undergo apoptosis and necrosis and produces a lesion that 
closely resembles Buruli ulcer when injected directly into 
guinea pig skin [42]. Although toxic lipid molecules are 
relatively commonly produced by mycobacteria, the synthesis 
of mycolactone itself appears to be restricted to M. ulcerans 
[43].
Prospects for developing a vaccine. There is no speciﬁ  c 
vaccine against M. ulcerans, but the M. bovis BCG vaccine 
offers some protection, albeit short lived [44,45]. BCG may 
possibly provide more enduring protection against the most 
severe forms of Buruli ulcer [46]. 
Current prospects for better vaccines include improved or 
repeated BCG vaccination, rational attenuation of a live M. 
ulcerans isolate, or subunit vaccines aimed at protein antigens 
or the toxin mycolactone itself [47]. 
Genome, bacterial population structure, and serodiagnosis. 
The expected publication of the whole M. ulcerans genome 
sequence in 2005 will mark a major milestone for Buruli ulcer 
researchers. Already the project has uncovered the presence 
of a large virulence plasmid that encodes mycolactone 
production proteins [48]. Biosynthesis of mycolactone 
requires three polyketide synthase enzymes and at least two 
accessory enzymes, all of which are located within a 110-kb 
cluster on this plasmid. The genome project has also revealed 
a remarkably high copy number of two insertion sequences, 
accounting for more than 5% of the total genome. There is 
evidence of considerable genome decay, with many potential 
pseudogenes and DNA deletions. These data coincide with 
accumulating evidence that suggests a reservoir in insects or 
other aquatic species and indicate that M. ulcerans may be 
passing through an evolutionary bottleneck as it adapts to life 
in a specialised niche environment. 
Molecular typing of M. ulcerans isolates has revealed a 
clonal population structure within speciﬁ  c geographical 
regions. Innovative genetic ﬁ  ngerprinting methods will 
be required to reveal local transmission pathways and 
environmental reservoirs. 
In endemic areas, clinical diagnosis of advanced Buruli 
ulcer lesions by experienced clinicians is quite reliable. 
Diagnostic conﬁ  dence can be increased by detecting acid-fast 
bacilli in smears or biopsies, and the diagnosis conﬁ  rmed 
by culture or PCR [49]. A recent report describes a new dry-
reagent PCR for Buruli ulcer that could be used in small 
regional centres, and reports from Ghana suggest a sensitivity 
of 95% [50]. Diagnosis of Buruli ulcer outside endemic areas 
or of pre-ulcerative lesions can be challenging. The genome 
sequence will greatly assist the development of a noninvasive 
serodiagnostic assay based on M. ulcerans–speciﬁ  c antigens. 
Conclusion
Buruli ulcer is now emerging from long years of neglect: 
interest and momentum are growing. However, there is much 
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Figure 3. Long-Term Sequelae of M. ulcerans Infection, Benin, West Africa 
(Photo: Kingsley Asiedu)
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Figure 4. Semi-Aquatic Hemiptera That Have Tested Positive for M. 
ulcerans 
The top row is Macrocoris sp., 1.0 centimeter in body length 
(Family Naucoridae), and the bottom row is Appasus sp., 
about 2.5 centimeters in body length (Family Belastomatidae). 
The ventral and dorsal views are in the left and right panels, 
respectively.PLoS Medicine  |  www.plosmedicine.org 0286
to do if we are to understand why the disease is becoming 
more common and how this relates to human activity. The 
current control strategy of early detection and treatment 
should be scaled up in the affected countries. Our ultimate 
goal is the development of an effective and safe vaccine 
able to provide long-lasting protection for those who live in 
endemic areas.  
A video about Buruli ulcer is freely available at http:⁄⁄www.who.
int/gtb-buruli/publications/video.htm.
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